Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — 3rd International World of Microbiome Conference 2022
15 slides from Microba Life Sciences's conference presentation, Apr 29, 2022
Slide 1: Microba to Present at International Microbiome Conference
ASX Announcement 29 April 2022 Microba to Present at International Microbiome Conference Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce Global Business Development lead, Mark Parker, will present at the 3rd International World of Microbiome Conference in
Slide 2: Microba's Discovery Platform: A unique dataset for discovery
For personal use only Microba’s Discovery Platform A unique dataset for discovery World of Microbiome | Vienna Mark Parker Global Business Development, Microba Life Sciences April 2022 | Authorised for release by the CEO and Chairman
Slide 3: Human gut microbiome is a critical factor in disease; fragmented datasets limit progress
There is unequivocal evidence demonstrating the human gut microbiome acts systemically and is a critical factor in disease For personal use only Deficient analysis and fragmented datasets are limiting progress • Incomplete measurement of gut microbiome communities • High error rates with existing to
Slide 4: Microba's data-driven discovery interrogates the novel microbiome
Microba’s data-driven discovery interrogates the novel microbiome For personal use only Microba 71% focuses on the 71% of the human microbiome that has so far resisted cultivation* Precision techniques developed by Microba enable access to greater depth and breath of the microbiome with precision an
Slide 5: Leading metagenomics analysis platform measures the microbiome with unparalleled performance
Microba’s leading metagenomics analysis platform measures the microbiome with unparalleled performance For personal use only Microba Microba Community Profiler Genome Database Metagenomic mapping technology World leading, expertly curated delivering leading microbiome microbial genome reference meas
Slide 6: In a real faecal sample, how much can be missed without precise analysis
In a real faecal sample, our analysis shows how much can be missed without precise metagenomic analysis For personal use only Type Cultured Uncultured MCP reports 10.0 181 species 7.5 MetaPhlAn reports Abundance 5.0 2.5 81 species 67% of community 33% of community diversity uncultured Cultured Data
Slide 7: Precision analysis generates a globally unique dataset to power discovery
Using precision microbiome analysis to generate a globally unique dataset to power microbiome discovery For personal use only Proprietary databank Novel >15,000 gut interventions metagenomes Biome Data and therapies Consistently collected Health, Medication, Data-driven discovery and analyzed cohort
Slide 8: Human first, data-driven approach to microbiome discovery and development
Human first, data-driven approach to microbiome discovery & development For personal use only Group AI & Advanced Drug Population testing comparison Disease Models Biostatistics Formulation Healthy Disease Analysis platform Discovery Platform Therapeutic Platform 7
Slide 9: Inflammatory Bowel Disease Program
Inflammatory Bowel Disease Program Demonstrating rapid translation from data to first in human For personal use only CANDIDATE SELECTION PROCESS Many bacteria Bacteria 4,784 Bacteria observed differentially abundant in prioritised based in Microba dataset health vs IBD on signal strength 18 months 1
Slide 10: Leads show strong in vitro therapeutic activity of cell migration and immune suppression
Leads show strong in vitro therapeutic activity of cell migration and immune suppression - further elucidating mechanism of action For personal use only Leads suppresses IL-23 mediated STAT3 activation Leads promotes epithelial cell migration – a key process – a crucial pathway in the uncontrolled i
Slide 11: Advanced AI and machine learning can discover strong signals from complex datasets
Advanced artificial intelligence and machine learning capabilities can discover strong signals from complex datasets For personal use only High resolution Species signatures Confounders species profiles associated with anxiety • Age Anxiety • Gender Predicted dietary dataset Dietary interventions to
Slide 12: Identifying microbiome leads using a big data approach and multiple methods
Identifying microbiome leads using a big data approach and multiple methods For personal use only 160 species significantly associated Machine learning methods improve confidence with anxiety (FDR < 0.05) in selected signals Top 10 species Health Anxiety Prevalence Data generated by Microba Life Sci
Slide 13: Opportunities for partnership to drive new discovery
Opportunities for partnership to drive new discovery For personal use only Analysis Platform Discovery Platform Therapeutic Platform End-to-end solution for A globally unique data resource Human first, data-driven precise and comprehensive and advanced capabilities in lead identification and microbi
Slide 14: Contact
Contact For personal use only Head Office Level 10, 324 Queen Street, Mark Parker Brisbane, QLD Australia Global Business Development Mark.parker@microba.com Laboratory Princess Alexandra Hospital, Brisbane, QLD Australia
Slide 15: Acknowledgements
Acknowledgements For personal use only Prof Gene Tyson Prof Phil Hugenholtz Dr Páraic Ó Cuív Dr Nicola Angel Blake Wills Dr Luke Holtham Dr Kylie Ellis Prof Ian Frazer Co-Founder, Co-Founder, Chair of VP Drug Discovery Laboratory Director Advisor, Strategic Alliances Chief Executive Officer Head of
Microba Life Sciences — 3rd International World of Microbiome Conference 2022 on 6ix